news

한어Русский языкEnglishFrançaisIndonesianSanskrit日本語DeutschPortuguêsΕλληνικάespañolItalianoSuomalainenLatina

according to the first financial news, guangzhou pharmaceutical group co., ltd. (hereinafter referred to as: guangzhou pharmaceutical group), the largest state-owned pharmaceutical company in south china, has experienced personnel shakeups again.

after the official announcement that li chuyuan, the former chairman of guangzhou pharmaceutical group, was under investigation, on the evening of september 1, baiyunshan pharmaceutical group's listed company (600332.sh; 00874.hk) once again disclosed an announcement stating that it had received the resignation report from the company's director zhang chunbo. "due to personal reasons," zhang chunbo resigned from the company's director and other positions and would no longer hold any position in the company.

yicai global's reporters confirmed from multiple independent sources that zhang chunbo had also been taken away by relevant departments for investigation. "last thursday, the group's leadership team was in a meeting, and then several staff members came in and took him away on the spot," a core insider of guangzhou pharmaceutical group told yicai global.

at the opening of the morning on september 1, the share price of baiyunshan a shares continued to fall. as of press time, the decline reached 2.74%, and the total market value of a shares reached 45.522 billion yuan.

young executives under investigation

unlike li chuyuan and other senior executives who are approaching the retirement age, zhang chunbo is a young executive among the leadership team of guangzhou pharmaceutical group. most employees regard him as the company's future "rising star".